68O Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC).

Authors :: Valle, J.W.
Qin, S.
Antonuzzo, L.
Tougeron, D.
Lee, C-K.
Tan, B.J.
Ikeda, M.
Guthrie, V.
McCoon, P.
Lee, Y.S.
Rokutanda, N.
Żotkiewicz, M.
Cohen, G.
Oh, D-Y.
Source :: Annals of Oncology. Nov2022 Suppl 9, Vol. 33, pS1457-S1457. 1p.
Publication Year :: 2022

Subjects :: *TREATMENT effectiveness
*CISPLATIN
*GEMCITABINE
*PLACEBOS
BILIARY tract cancer

Full Text Access

Tools